Validation of Academic Research Consortium for High Bleeding Risk Definition in East-Asian Patients

Figures

• 

  Figure 1. Cumulative Incidence of Primary Endpoint at 12 Months Kaplan-Meier curves show the rates of the primary bleeding endpoint of BARC 3 or 5 bleeding (A) and the primary ischemic endpoint of MACE (B). MACE was defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. BARC = Bleeding Academic Research Consortium; HBR = high bleeding risk; MACE = major adverse cardiac event(s).

• 

  Figure 2. Cumulative Incidence of Primary Endpoint Stratified by Antiplatelet and HBR Kaplan-Meier curves show the rates of the primary bleeding endpoint of BARC 3 or 5 bleeding (A) and the primary ischemic endpoint of MACE (B). MACE was defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Abbreviations as in Figure 1.

• 

  Central Illustration. Prognostic and Differential Impact of ARC-HBR Definition Kaplan-Meier curves of primary bleeding and ischemic endpoints at 12 mo according to presence or absence of HBR and stratified by presence of HBR characteristics. The cumulative incidence of the primary bleeding and endpoint of BARC type 3 or 5 based on HBR (A). The cumulative incidence of the primary ischemic endpoint of major adverse cardiovascular events based on HBR (B). The cumulative incidence of the primary bleeding endpoint of bleeding academic research consortium (BARC) type 3 or 5 based on HBR patients taking ticagrelor vs clopidogrel (C). The cumulative incidence of the primary ischemic endpoint of major adverse cardiovascular events based on HBR patients who take ticagrelor vs clopidogrel (D). ARC-HBR = Academic Research Consortium High Bleeding Risk; BARC = Bleeding Academic Research Consortium; HBR = high bleeding risk.